Uy Ear
Stock Analyst at Mizuho
(3.71)
# 1,274
Out of 4,479 analysts
53
Total ratings
44.44%
Success rate
10.34%
Average return
Main Sectors:
13 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RNAC Cartesian Therapeutics | Initiates: Buy | $40 | $24.27 | +64.81% | 1 | May 24, 2024 | |
| SRPT Sarepta Therapeutics | Maintains: Buy | $145 → $179 | $156.75 | +14.19% | 5 | May 17, 2024 | |
| ARQT Arcutis Biotherapeutics | Maintains: Buy | $17 → $18 | $9.56 | +88.28% | 11 | May 15, 2024 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Neutral | $25 → $21 | $16.04 | +30.92% | 10 | May 9, 2024 | |
| QURE uniQure | Maintains: Neutral | $7 → $6 | $4.45 | +34.98% | 3 | May 8, 2024 | |
| SAGE Sage Therapeutics | Maintains: Neutral | $20 → $18 | $11.03 | +63.19% | 1 | Apr 26, 2024 | |
| EOLS Evolus | Maintains: Buy | $20 → $23 | $11.08 | +107.58% | 3 | Mar 8, 2024 | |
| NBIX Neurocrine Biosciences | Maintains: Neutral | $116 → $140 | $140.11 | -0.08% | 10 | Feb 8, 2024 | |
| RVNC Revance Therapeutics | Maintains: Buy | $35 → $16 | $2.57 | +522.57% | 1 | Nov 22, 2023 | |
| ALKS Alkermes | Maintains: Buy | $37 → $35 | $24.39 | +43.50% | 4 | Oct 26, 2023 | |
| JNJ Johnson & Johnson | Maintains: Buy | $36 → $40 | $146.44 | -72.69% | 1 | Jun 7, 2023 | |
| CABA Cabaletta Bio | Reiterates: Buy | $10 | $7.81 | +28.04% | 1 | Mar 17, 2023 | |
| OCGN Ocugen | Maintains: Buy | $5 → $3 | $1.63 | +84.62% | 2 | Mar 1, 2023 |
Cartesian Therapeutics
May 24, 2024
Initiates: Buy
Price Target: $40
Current: $24.27
Upside: +64.81%
Sarepta Therapeutics
May 17, 2024
Maintains: Buy
Price Target: $145 → $179
Current: $156.75
Upside: +14.19%
Arcutis Biotherapeutics
May 15, 2024
Maintains: Buy
Price Target: $17 → $18
Current: $9.56
Upside: +88.28%
ACADIA Pharmaceuticals
May 9, 2024
Maintains: Neutral
Price Target: $25 → $21
Current: $16.04
Upside: +30.92%
uniQure
May 8, 2024
Maintains: Neutral
Price Target: $7 → $6
Current: $4.45
Upside: +34.98%
Sage Therapeutics
Apr 26, 2024
Maintains: Neutral
Price Target: $20 → $18
Current: $11.03
Upside: +63.19%
Evolus
Mar 8, 2024
Maintains: Buy
Price Target: $20 → $23
Current: $11.08
Upside: +107.58%
Neurocrine Biosciences
Feb 8, 2024
Maintains: Neutral
Price Target: $116 → $140
Current: $140.11
Upside: -0.08%
Revance Therapeutics
Nov 22, 2023
Maintains: Buy
Price Target: $35 → $16
Current: $2.57
Upside: +522.57%
Alkermes
Oct 26, 2023
Maintains: Buy
Price Target: $37 → $35
Current: $24.39
Upside: +43.50%
Johnson & Johnson
Jun 7, 2023
Maintains: Buy
Price Target: $36 → $40
Current: $146.44
Upside: -72.69%
Cabaletta Bio
Mar 17, 2023
Reiterates: Buy
Price Target: $10
Current: $7.81
Upside: +28.04%
Ocugen
Mar 1, 2023
Maintains: Buy
Price Target: $5 → $3
Current: $1.63
Upside: +84.62%